Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
Inventors
Li, An-Hu • Sakilam, Satish Kumar • Lim, Dong Sung
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11370783-B2
Publication Date
2022-06-28
Expiration Date
Abstract
The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
Core Innovation
The invention relates to Compound 1 provided in a solid form that is or comprises Form A, where Form A is characterized by peaks in its X-ray powder diffraction pattern selected from those at about 8.64, about 11.04, about 17.34, about 25.06, and about 25.70 degrees 2-theta. The solid form is formulated into a liquid composition for aqueous buffered saline administration.
The disclosed embodiments also include crystalline, solvated, and unsolvated solid forms of Compound 1, including propylene glycol solvate Form C and ethylene glycol solvate Form D. The solid forms are characterized using XRPD peak sets and additional solid-state characterization such as TGA/DSC, with reported stability behavior to moisture, temperature, and UV and solid-state stability and conversion behavior among forms.
The invention further includes mixtures of solid forms, including mixtures of Form A and Form C, mixtures of Form A and Form D, and a mixture containing Compound 1 Form A solid form and amorphous Compound 1. The disclosed solid forms can be formulated into pharmaceutical compositions to modulate HGF/SF activity.
Claims Coverage
The independent claims identified from the provided claim set include one independent claim. Across the claim set, the inventive features focus on providing Compound 1 in a solid form that is or comprises Form A defined by specified XRPD peaks and formulating it into an aqueous buffered saline liquid composition containing defined proportions of polyethylene glycol 300 and polysorbate 80, with dependent claims further narrowing buffer identity, concentration range, and suitability for intravenous administration.
X-ray powder diffraction-defined Form A solid form of Compound 1
Providing Compound 1 in a solid form that is or comprises Form A, wherein Form A is characterized by one or more peaks in its X-ray powder diffraction pattern selected from those at about 8.64, about 11.04, about 17.34, about 25.06, and about 25.70 degrees 2-theta.
Aqueous buffered saline liquid formulation with PEG 300 and polysorbate 80
Formulating the Compound 1 in aqueous buffered saline comprising about 40% (v/v) to about 60% (v/v) polyethylene glycol 300 and about 5% (v/v) to about 15% (v/v) polysorbate 80.
Phosphate-buffered saline aqueous buffered saline
Using phosphate-buffered saline as the aqueous buffered saline.
Concentration range of Compound 1 in the liquid composition
Performing the method with a composition containing about 0.8 mg/mL to about 10 mg/mL of Compound 1.
Locked polyethylene glycol 300 proportion
Performing the method with a composition that contains about 50% (v/v) polyethylene glycol 300.
Intravenous administration suitability
Limiting the method to a composition that is suitable for intravenous administration.
Mixture of Form A solid form and amorphous Compound 1
Further provides Compound 1 as a mixture containing Compound 1 Form A solid form and amorphous Compound 1.
Overall, the claim coverage centers on a Form A-defined solid form of Compound 1 characterized by specified XRPD peaks and a liquid composition in aqueous buffered saline with defined polyethylene glycol 300 and polysorbate 80 proportions. Dependent claims further specify phosphate-buffered saline, quantitative concentration and component content ranges and values, suitability for intravenous administration, and inclusion of a mixture of Form A solid and amorphous Compound 1.
Stated Advantages
The liquid composition is tied to a controllable solid-state starting material.
Documented Applications
Pharmaceutical compositions for modulating HGF/SF activity.
Interested in licensing this patent?